On April 25, "Pharmaceutical Excipients Technology Seminar ·Guangzhou Station" jointly organized by Standard Pharma, JRS (Germany), Meggle (Germany)and SSP (Sino-German Joint Venture), was grandly held in Guangzhou Hilton Hotel, with a warm and lively atmosphere, showcasing numerous highlights.
More than 150 professionals from pharmaceutical companies and R&D institutes are gathered at the site.
The seminar covered a wide range of hot topics, including but not limited to the application of new excipient products, solutions to common problems in formulation development, and solutions for poorly soluble drugs, and also analyzed the macro-level of "the benefits of building a long-term stable and reliable supply chain for cost reduction and efficiency enhancement for enterprises".
As the organizer of the seminar, Ms. Christine Lin, President of Standard pharma, highlighted the company's profile and API business. Standard pharma's one-stop service helps customers "optimize the old products and develop new products", earning the trust and cooperation of over 3,000 pharmaceutical, health product, and R&D enterprises.
During the networking break, the equipment and samples displayed at the conference attracted the attention of many participants, who interacted with gaining in-depth knowledge of the equipment and products.
In the Q&A session, the participants engaged in in-depth discussions around the topics, the site has a warm response, frequent interaction, and all questions raised by the attendees received detailed answers.
At the end of the meeting, Mr. Yonghong Guan, General manager of Standard Pharma, delivered a concluding speech. He expressed heartfelt gratitude to all the pharmaceutical industry colleagues, and also thanked the professional and technical teams of JRS (Germany), Meggle (Germany) and SSP (Sino-German Joint Venture). The seminar's topics were well-received by the attendees.
Mr. Yonghong Guan also expressed the hope that this seminar would serve as an opportunity to establish closer cooperative relationships with everyone, achieve complementary advantages, and jointly inject more vitality and innovation into the development of the pharmaceutical industry.
